The present protocol will utilize simultaneous recording of brain activity during attention
and memory tasks in insomnia participants after ramelteon vs. zolpidem vs. placebo
administration. The investigators hypothesize that amplitudes of associated with memory
will be unchanged by ramelteon, whereas zolpidem will significantly reduce brain activity
associated with stimulus processing as evidenced by abnormal reduction in the amplitude of
specific brain regions relative to placebo.
The proposed research has two specific aims: 1) demonstrate that ramelteon has no effect on
event related potential components that reflect basic sensory processes (P1 and N1), and
will not impair attention and memory processes, whereas the benzodiazepine receptor agonist
zolpidem will significantly reduce (relative to placebo) the amplitude of these event
related potential components throughout the cerebral cortex and 2) show that ramelteon
reduces the abnormal hyperarousal in insomnia as reflected through a reduction in the
contingent negative variation component of the event related potential across frontal and
parietal brain regions.
- Healthy individuals with no secondary condition to insomnia.
- Healthy individuals with no insomnia.